Immunosuppression and immunomodulation in Sjogren's syndrome - What is the evidence? Does it relieve the sicca symptoms?

see the original item page
in the repository's web site and access all digital files if the item*



Immunosuppression and immunomodulation in Sjogren's syndrome - What is the evidence? Does it relieve the sicca symptoms? (EN)

Moutsopoulos, HM (EN)
Mavragani, CP (EN)

journalArticle (EN)

2014-03-01T01:54:36Z
2005 (EN)


Sjogren's syndrome (SS), is a chronic autoimmune disorder, characterized by lymphocytic infiltration and destruction of the exocrine glands (mainly the salivary and the lacrimal glands) resulting in dry mouth and eyes. The symptoms of SS are chronic and sometimes devastating, compromising the quality of life at a major extent. Although SS is considered a classical autoimmune disorder, evidence for the use of immunosuppressive agents, the mainstay of therapy of diseases of autoimmune origin, is scarce. Cholinergic agents, such as pilocarpine and cevimeline are the cornerstone of current therapy of SS, while oral interferon and ciclosporine ocular drops seem to be of some benefit. In contrast, other immunosuppressive substances, such as methotrexate, azathioprine or anti-TNF agents, did not alleviate the sicca features associated with the disease. Corticosteroids, cyclophosphamide and nucleoside analogues are reserved for life threatening severe extraglandular manifestations of SS. (EN)

Rheumatology (EN)

immunomodulation (EN)
CONTROLLED-TRIAL (EN)
PLACEBO (EN)
MULTICENTER (EN)
Sjogren's Syndrome (SS) (EN)
XEROSTOMIA (EN)
immunosuppression (EN)
ALPHA (EN)
CEVIMELINE (EN)
autoimmune disease (EN)
SALIVARY (EN)
DRY EYE (EN)
DOUBLE-BLIND (EN)
INFLIXIMAB (EN)

AKTUELLE RHEUMATOLOGIE (EN)

German

GEORG THIEME VERLAG KG (EN)




*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)